PMID- 36937847
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230321
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - Pharmacokinetic study of Strongylocentrotus nudus egg polysaccharide in rats and 
      beagles using a (3)H-labeling method.
PG  - 1109084
LID - 10.3389/fphar.2023.1109084 [doi]
LID - 1109084
AB  - Strongylocentrotus nudus egg polysaccharide (SEP) extracted from sea urchins has 
      potential anticancer activity. However, little is known about its pharmacokinetic 
      properties. To investigate the pharmacokinetics of SEP, it was radiolabeled with 
      tritium. Furthermore, a sensitive, selective, and rapid liquid scintillation 
      counter (LSC) method for quantifying (3)H-SEP in biological matrix was validated. 
      The lower quantification limit of the method was 4 Bq. The relative standard 
      deviations (RSDs) of the intra- and inter-day precision were <3.0% and <3.9%, 
      respectively. (3)H-SEP was successfully applied to investigate the 
      pharmacokinetics of SEP after intravenous administration of 20, 40, and 80 mg/kg 
      (40 muCi/kg) in rats and 5, 10, and 20 mg/kg (6 muCi/kg) in beagles. The AUC((0-t)) 
      of SEP at three different doses was 487.81 +/- 39.99 mg/L*h, 1,003.10 +/- 
      95.94 mg/L*h, and 2,188.84 +/- 137.73 mg/L*h in rats and 144.12 +/- 3.78 mg/L*h, 
      322.62 +/- 28.03 mg/L*h, and 754.17 +/- 37.79 mg/L*h in beagles. The terminal 
      elimination half-life (t(1/2)) of SEP was longer in beagles (204.29 +/- 139.34 h) 
      than in rats (35.48 +/- 6.04 h). The concentration of SEP in plasma declined 
      rapidly in both rats and beagles. All the study results provide detailed 
      pharmacokinetic profiles of SEP in two kinds of animals, which will be helpful 
      for further development.
CI  - Copyright (c) 2023 Xing, Zhu, Liao, Kong, Lu, Zhao, Li, Chen and Qin.
FAU - Xing, Han
AU  - Xing H
AD  - Department of Pharmacy, First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
AD  - Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, 
      Zhengzhou, China.
AD  - Henan Engineering Research Center for Application and Translation of Precision 
      Clinical Pharmacy, Zhengzhou University, Zhengzhou, China.
FAU - Zhu, Xiaojie
AU  - Zhu X
AD  - Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, 
      Jiangsu Province, China.
FAU - Liao, Jianmin
AU  - Liao J
AD  - Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, 
      Jiangsu Province, China.
FAU - Kong, Ying
AU  - Kong Y
AD  - Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, 
      Jiangsu Province, China.
FAU - Lu, Yayuan
AU  - Lu Y
AD  - Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, 
      Jiangsu Province, China.
FAU - Zhao, Di
AU  - Zhao D
AD  - Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, 
      Jiangsu Province, China.
FAU - Li, Ning
AU  - Li N
AD  - Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, 
      Jiangsu Province, China.
FAU - Chen, Xijing
AU  - Chen X
AD  - Clinical Pharmacokinetics Laboratory, China Pharmaceutical University, Nanjing, 
      Jiangsu Province, China.
FAU - Qin, Zhiying
AU  - Qin Z
AD  - Department of Pharmacy, First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
AD  - Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, 
      Zhengzhou, China.
AD  - Henan Engineering Research Center for Application and Translation of Precision 
      Clinical Pharmacy, Zhengzhou University, Zhengzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20230302
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10017969
OTO - NOTNLM
OT  - 3H-labeling method
OT  - Strongylocentrotus nudus egg polysaccharide
OT  - beagles
OT  - pharmacokinetics
OT  - rats
OT  - tritium
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/03/21 06:00
MHDA- 2023/03/21 06:01
PMCR- 2023/03/02
CRDT- 2023/03/20 04:10
PHST- 2022/11/27 00:00 [received]
PHST- 2023/02/10 00:00 [accepted]
PHST- 2023/03/20 04:10 [entrez]
PHST- 2023/03/21 06:00 [pubmed]
PHST- 2023/03/21 06:01 [medline]
PHST- 2023/03/02 00:00 [pmc-release]
AID - 1109084 [pii]
AID - 10.3389/fphar.2023.1109084 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Mar 2;14:1109084. doi: 10.3389/fphar.2023.1109084. 
      eCollection 2023.